Slide 1: Advanced analytics. Intelligent insights. FY23 Results
Advanced analytics. Intelligent insights. FY23 Results 5th December 2023 Giulio Cerroni Grant Nash Robin Wolz CEO CFO CSO
Slide 2: Nonregulated Disclaimer
Nonregulated Disclaimer This presentation is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing which accompanies it. The information in this presentation is subject to updating, revision and amendment. The information in this presentation, which incl
Slide 3: Precision Medicine. Precision in Neuroscience
Precision Medicine. Precision in Neuroscience 3
Slide 4: Driven By Our Purpose
Driven By Our Purpose Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience. We will focus on developing and deploying breakthrough data analytics, at scale, through our remote-access technology pla
Slide 5: Precision in Neuroscience Strategy
Precision in Neuroscience Strategy Build Innovate Penetrate Bridge Enhance …commercial … by extending …early phase trials …the clinical …growth via reach & iCRO our data assets to grow into later trial to clinical partnerships scale & leading AI clinical phases practice divide and M&A biomarker port
Slide 6: Share price tracking revenues, but IXICO value is in longer term return
Share price tracking revenues, but IXICO value is in longer term return that will come from Science and Technology assets £1.24 £0.26 9.5 9.2 8.6 £0.15* 6.7 6.1 5.4 2018 2019 2020 2021 2022 2023 *As at 1 December 2023 6 PUBLIC © IXICO plc 2023
Slide 7: Leading with Science
Leading with Science Patient Earlier Healthcare Ageing New Precision Fast track Screening intervention system population therapies Medicine approvals readiness AI automated brain imaging biomarker analytics platform New and better biomarkers Translational science Partnering with Academia in Major Fi
Slide 8: Scientific Partnerships
Trusted CNS iCRO partner – 20 year industry track record Top Pharma* Abbvie – Janssen – Novartis Roche – Sanofi – GSK – Takeda Scientific Partnerships Biopharma Partners Eli Lilly – Novo Nordisk Mid Pharma* Biogen – Merck – Eisai Biotech* PTC Therapeutics – ASK Bio – TauRx Uniqure – ACImmune – Lundb
Slide 9: Financial Highlights FY2023
Financial Highlights FY2023 9
Slide 10: Challenging market conditions delay return to growth
Challenging market conditions delay return to growth 98 FTEs 9.5 9.2 67 8.6 65 66 1.7 7.6 61 1.5 1.5 75 6.7 59 5.4 62 49 0.4 -0.7 -0.8 2018 2019 2020 2021 2022 2023 2018 2019 2020 2021 2022 2023 2018 2019 2020 2021 2022 2023 ▪ Final year of impact from the cessation of the ▪ Gross margin reflects: ▪
Slide 11: Investment delivery; balance sheet reflects long-term value of science and tech assets
Investment delivery; balance sheet reflects long-term value of science and tech assets 2.6 7.9 7.9 2.3 12.5 7.3 11.5 11.4 6.7 1.9 5.8 9.4 7.3 7.9 4.0 1.2 0.6 0.1 2018 2019 2020 2021 2022 2023 2018 2019 2020 2021 2022 2023 2018 2019 2020 2021 2022 2023 ▪ £4.0m debt-free cash position ▪ Investments in
Slide 12: Order book impacted by slower bookings but remains strong
Order book impacted by slower bookings but remains strong 21.7 19.3 18.8 15.9 16.0 6.7 14.8 8.0 16.0 2.5 14.8 2018 2019 2020 2021 2022 2023 30-Sep-22 Revenues Client trial Trial wins 30-Sep-23 descopes and fx ▪ £14.8m of future years’ revenues contracted at 30-Sep-23 ▪ £8.0m contract wins; New contr
Slide 13: Order book diversified across trial phases, clients and indications
Order book diversified across trial phases, clients and indications 1.2 0.2 0.1 1.5 4.1 1.0 0.6 0.4 1.0 0.2 9.3 2.4 3.1 17.4 6.2 9.9 7.6 6.8 3.5 7.6 2.9 0.8 4.9 4.4 4.2 2.2 2.3 0.8 2018 2019 2020 2021 2022 2023 1 2 3 NH Other ▪ Orderbook >75% early phase trials ▪ Average project lower in value, but
Slide 14: Order book diversified across trial phases, clients and indications
Order book diversified across trial phases, clients and indications 2018 2019 2020 2021 2022 2023 ▪ 15 clients, 20 projects and 7 therapeutic indications in our orderbook at 30-Sep-23 ▪ Client base a mix of top pharma (c.15%), mid-pharma (c.20%), biotech (c.50%) and charity (c.15%) ▪ Top client 20%
Slide 15: Next Generation Trial Tracker
Next Generation Trial Tracker 15
Slide 16: TrialTracker: IXICO's end-to-end image capture and analysis platform
TrialTracker: IXICO’s end-to-end image capture and analysis platform Standardised capture, analysis and reporting Site of regulatory compliant clinical data Sponsor Pharma / Biotech MR images Clinical sponsor interpretation standardized Clinical development expert reads Support the development of dr
Slide 17: Next generation TrialTracker
Precision in Neuroscience Strategy Build Innovate Penetrate Bridge Enhance …commercial … by extending …early phase …the clinical …growth via reach & iCRO our data assets trials to grow into trial to clinical partnerships scale & leading AI later clinical phases practice divide and M&A biomarker port
Slide 18: Flexible & scalable custom workflow engine built on MS Azure technologies
Flexible & scalable custom workflow engine built on MS Azure technologies Container Registry Flexible VM families Unlimited Cloud Scaling Kubernetes Cluster App Services Storage Queues Function Apps Workflow Engine Azure Files Cosmos DB 18 Persistent Cloud Storage PUBLIC © IXICO plc 2023
Slide 19: Leading with Science
Leading with Science 19
Slide 20: Case study: AI-driven imaging biomarkers in Huntington's disease
Case study: AI-driven imaging biomarkers in Huntington’s disease MRI-based patient selection in HD IXICO’s IXIQ.Ai is underpinning a new initiative to establish the reference approach for the Huntington's Disease Integrated Staging System (HD-ISS) “We developed the HD-ISS using state-of-the-art evid
Slide 21: Established world class MRI offering
Established world class MRI offering IM AGINGStructural MRI Susceptibility BIOSENSOR Diffusion MRI DTI Volumetrics Analysis Radiological (dMRI) (T1w, T2w) (Cross-sectional (SWI, QSM) Read (incl. CMB) and Longitudinal) (SWI) Structural Connectivity ROI Hippocampal segmentations subfields (SWI, QSM) N
Slide 22: New: extended molecular imaging offering
New: extended molecular imaging offering Dopamine Amyloid Central Visual Tau read (PET & SPECT) Visual Standardized Central Visual read Uptake Value Ratio (SUVR) read Quantitative Semi-quantitative Standardized read (e.g. visQ) Uptake Value analysis Ratio (SUVR) Centiloid Glucose Inflammation Centra
Slide 23: Leading with science – progressing AD biomarkers
Leading with science – progressing AD biomarkers …plus more than 10 conference presentations 23 PUBLIC © IXICO plc 2023
Slide 24: AD drug development landscape
AD drug development landscape Diverse set of mechanism of action in Phase 2 (N=87) Moving towards precision medicine Proteostasis/ Proteinopathies (n=3) Synaptic plasticity/ Amyloid (N=11) 3% Neuroprotection 13% (n=12) Vasculature (n=3) 16% 2% Tau (N=8) 9% Metabolism/ Bioenergetics (n=4) Inflammatio
Slide 25: MRI and PET to support multi-biomarker phenotyping
MRI and PET to support multi-biomarker phenotyping Amyloid • Amyloid PET: well established; standardized analysis across Proteostasis/ tracers (centiloid scale [1]) Proteinopathies (n=3) Tau Synaptic plasticity/ Amyloid (N=11) 3% • Tau PET: increasing validation / tracer availability; standardizatio
Slide 26: New R&D project: multi-biomarker AD diagnosis
New R&D project: multi-biomarker AD diagnosis 12-month partnership project to develop AI technology for stratification and differential dementia diagnosis • Technology can support streamlines clinical trial screening with an increasing number of biomarkers • Enables potential support of emerging cli
Slide 27: Summary highlights
Summary highlights 27
Slide 28: Significant, growing unmet clinical need in neurological diseases
Significant, growing unmet clinical need in neurological diseases Increasing costs Dementia is the only major Total worldwide Ageing population & burden to cause of death we can’t cost of dementia (2) The number of 131.5m global healthcare prevent, slow people in the world down or cure (1) with deme
Slide 29: Precision in Neuroscience Strategy
Precision in Neuroscience Strategy Build Innovate Penetrate Bridge Enhance …commercial … by extending …early phase trials …the clinical trial …growth via reach & iCRO our data assets to grow into later to clinical practice partnerships scale & leading AI clinical phases divide and M&A biomarker port
Slide 30: Thank You
® ea Thank: You ; f
Slide 31: Appendix slides
Appendix slides 31
Slide 32: Major shareholders (>3% holding) as at December-23
Major shareholders (>3% holding) as at December-23 Percentage Shareholder Date acquired No. of Shares allocation BGF Investment Management May-19 8,924,000 18% Octopus Investments May-18 6,408,400 13% Gresham House May-18 5,357,100 11% Amati Global Investors May-18 5,031,300 10% CIP Merchant Capital
Slide 33: Summary Income Statement
Summary Income Statement Income Statement FY2023 FY2022 £’000 £’000 Revenues 6,665 8,643 YoY% decline (23%) (4%) Gross profit 3,270 5,243 Gross margin % 49% 61% Other income 393 689 R&D 925 1,217 S&M 1,321 1,226 G&A 2,854 2,581 Total operating expenses 5,100 5,024 Operating (loss)/profit (1,437) 908
Slide 34: Summary Balance Sheet
Summary Balance Sheet Balance Sheet FY2023 FY2022 £’000 £’000 Tangible & intangible assets 6,704 5,404 Current assets 2,255 3,482 Cash 4,031 5,769 Current liabilities (1,281) (1,735) Total working capital 5,005 7,516 Non-current liabilities (277) (427) Total net assets 11,432 12,493 Share capital an
Slide 35: Summary Cashflow
Summary Cashflow Cashflow FY2023 FY2022 £’000 £’000 Cashflow from operating 302 1,424 Cashflow from investing (1,864) (2,239) Cashing flow from financing (156) (114) Movement in cash (1,718) (929) Opening cash 5,769 6,684 Effect of FX (20) 14 Closing cash 4,031 5,769 35 PUBLIC © IXICO plc 2023